Xtant Medical Holdings, Inc. (NYSE American: XTNT) Reports Earnings, Surpasses Revenue Estimates

Core Insights - Xtant Medical Holdings, Inc. reported an earnings per share (EPS) of -$0.005, matching estimates, with revenue of approximately $33.26 million, exceeding expectations of $32.70 million [1][6] Financial Performance - The company achieved a total revenue of $33.26 million in the third quarter of 2025, reflecting a 19% increase compared to the previous year [2][6] - XTNT's full-year 2025 revenue guidance remains between $131 million and $135 million, indicating an anticipated growth of 11% to 15% over fiscal year 2024 [3][6] - Despite a negative price-to-earnings (P/E) ratio of -23.14, the price-to-sales ratio stands at 0.78, suggesting the stock is valued at less than one times its sales [2] Strategic Initiatives - The company announced the sale of certain hardware assets and its OUS businesses to Companion Spine, expected to close by the end of the year, which may enhance focus on core operations and improve financial performance [3][6] - Sean Browne, President and CEO, emphasized the company's commitment to self-sustainability through positive free cash flow, as reflected in the strong third-quarter results [4] Liquidity and Debt Position - XTNT maintains a strong liquidity position with a current ratio of 2.47, indicating more than twice the current assets compared to current liabilities [5] - The debt-to-equity ratio is 0.31, suggesting a moderate level of debt relative to equity [5]